{"entity":{"id":"nct03878849","kind":"trial","name":"Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer","aka":[],"tldr":"A phase 2 trial of 2X-121 in ovarian cancer, run by Allarity Therapeutics, now recruiting.","summary":"Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer is a phase 2 interventional study registered as NCT03878849 by Allarity Therapeutics, with 40 participants planned, started 2019-04-15 and due to reach its primary completion in 2027-03. Interventions recorded: 2X-121.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03878849","url":"https://clinicaltrials.gov/study/NCT03878849"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03878849","phase":"2","setting":"Phase 2, Randomized, Prospective, Open-Label, Parallel-Arm, Dose Optimization Study to Investigate the Safety, Tolerability, PK/PD, and Anti- Tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer.","sponsor":"Allarity Therapeutics","enrolled":40,"outcomes":[]},"route":"/trials/nct03878849/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}]}}